- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05472818
SV2A Density Cannabis Use Disorder
February 28, 2024 updated by: Deepak C. D'Souza, Yale University
The main purpose of this study is to determine whether hippocampal synaptic vesicle density estimated by hippocampal [11C]APP-311/[11C]UCB-J binding in individuals diagnosed with cannabis use disorder (CUDs) improves with at least 4 weeks of confirmed abstinence from cannabis, in comparison to healthy controls (HCs).
Furthermore, any change in synaptic vesicle density will be placed in functional context by measuring verbal memory, which is sensitive to hippocampal function, before and after at least 4 weeks of confirmed abstinence.
Finally, the relationship between hippocampal [11C]UCB-J binding in CUDs with measures of cannabis exposure (e.g., age of initiation, cumulative lifetime dose) will be explored.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
42
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anika Kumar
- Phone Number: (203) 974-7525
- Email: anika.kumar@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Recruiting
- Yale University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
CUD Participants Inclusion Criteria:
- Able to provide informed consent
- Male and female 18-75 years old
- Daily cannabis use
- Positive urine screen for cannabinoids and negative for all other drugs on
- Diagnosis of DSM-5 cannabis use disorder (≥ moderate, i.e., ≥ 4 [of 11] symptoms).
- Must express a willingness at screening to set a date to attempt to quit using cannabis.
- Physically healthy i.e., no clinically unstable medical conditions.
- For women of childbearing potential (WOCBP) and men, willingness to practice birth control and to inform study staff immediately if either they (for women) or their partner (for men) becomes pregnant.
- Additional criteria not disclosed here in order to minimize the risk of ineligible subjects enrolling in the study.
CUD Participants Exclusion Criteria:
- Laboratory tests with clinically significant abnormalities or positive urine toxicology screen with exception of cannabinoids.
- Women with a positive pregnancy test or women who are lactating.
- Have implanted or embedded metal objects or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked with ferrous metals either as a vocation or hobby (for example, as a sheet metal worker, welder, or machinist) in such a way that might have led to unknown, indwelling metal fragments that could cause injury if they moved in response to placement in the magnetic field
- Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits.
- History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto) Subjects who have donated blood within 8 weeks of the present study
- Medications that could alter synaptic density and, therefore, confound the interpretation of study data.
- Additional criteria not disclosed here in order to minimize the risk of ineligible subjects enrolling in the study.
Healthy Controls Inclusion Criteria:
- Willing and able to give voluntary written informed consent
- Male and Female subjects, age 18 to 75 years, inclusive
- BMI within 19 to 35 kg/m2, inclusive
- Must be in good health as determined by medical history, physical examination, ECG, serum/urine biochemistry, hematology, and serology tests.
- Negative urine drug screen
- If female, not pregnant or breastfeeding
- If female of childbearing potential, must agree to use an acceptable method of birth control, as determined by the principal investigator, for the duration of the study and up to one month after completion of PET scans.
- Able to read and write, able to communicate effectively with the investigator, and comply with all study requirements, restrictions, and directions of the clinic staff.
- Have arterial access sufficient to allow blood sampling as per the protocol.
Healthy Controls Exclusion Criteria:
- History or presence of clinically significant and unstable respiratory, GI, renal, hepatic, pancreatic, hematological, neurological (including history of seizure), cardiovascular, psychiatric (including known addictive disorders), musculoskeletal, genitourinary, immunological, or dermatological disorders, including all cancers.
- Abnormal clinically significant laboratory or physical findings during screening
- History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto)
- A condition that, in the opinion of the investigator, would prevent compliance with the study protocol.
- Medications that could alter synaptic density and, therefore, confound the interpretation of study data.
- MRI incompatible implants and other contraindications for MRI, such as pace-maker, artificial joints, non-removable body piercings, metal fragments in head and/or body, or history working with ferrous metals either as a vocation or hobby in such a way that might have led to unknown, indwelling metal fragments that could cause injury during MRI etc.
- Subjects who suffer from claustrophobia.
- Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits for healthy volunteers
- Additional criteria not disclosed here in order to minimize the risk of ineligible subjects enrolling in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CUD Group
Participants will be scanned using anatomical magnetic resonance imaging (MRI) and PET.
All participants will receive two PET scans, 4 weeks apart.
CUD participants will be asked to abstain from cannabis for the 4 week period.
|
For each [11C]APP311 (UCB-J) PET scan, up to 20 mCi of [11C]APP311 (UCB-J) will be administered by infusion pump.
All participants will receive at least two [11C]APP311 (UCB-J) PET scans approx.
4 weeks days apart.
Approximately 8 CUD participants will be asked to return for a third [11C]APP311 (UCB-J) PET scan after an additional 4 weeks following their second scan.
|
Active Comparator: Healthy Controls
Participants will be scanned using anatomical magnetic resonance imaging (MRI) and PET.
All participants will receive two PET scans, 4 weeks apart.
|
For each [11C]APP311 (UCB-J) PET scan, up to 20 mCi of [11C]APP311 (UCB-J) will be administered by infusion pump.
All participants will receive at least two [11C]APP311 (UCB-J) PET scans approx.
4 weeks days apart.
Approximately 8 CUD participants will be asked to return for a third [11C]APP311 (UCB-J) PET scan after an additional 4 weeks following their second scan.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hippocampal SV2A synaptic density
Time Frame: All participants will receive at least two [11C]APP311 (UCB-J) PET scans approx. 4 weeks days apart.
|
Hippocampal SV2A synaptic density will be measured using [11C]APP311 (UCB-J).
|
All participants will receive at least two [11C]APP311 (UCB-J) PET scans approx. 4 weeks days apart.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hippocampal binding and Hippocampal Verbal Memory Task
Time Frame: The Auditory Verbal Learning Task (AVLT) will be administered before and after the 4 week abstinence period.
|
To determine the relationship between hippocampal [11C]APP311 (UCB-J) binding and performance on the hippocampal verbal memory task (Auditory Verbal Learning Task [AVLT]), a cognitive task that measures total immediate recall, before and after 4 weeks of confirmed cannabis abstinence.
|
The Auditory Verbal Learning Task (AVLT) will be administered before and after the 4 week abstinence period.
|
Hippocampal binding and Groton Maze Learning in CUDs
Time Frame: The Groton Maze Learning Task will be administered before and after the 4 week abstinence period.
|
To determine the relationship between hippocampal [11C]APP311 (UCB-J) binding and performance on the Groton Maze Learning task, a cognitive task that measures total number of errors, in CUDs before and after 4 weeks of confirmed cannabis abstinence.
|
The Groton Maze Learning Task will be administered before and after the 4 week abstinence period.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hippocampal synaptic density and first age of cannabis exposure
Time Frame: Before and after the 4 week abstinence period.
|
To determine the relationship between hippocampal synaptic density (n=26+12 historical data) and indices of cannabis exposure such as first age of cannabis exposure, as measured by self-report data.
|
Before and after the 4 week abstinence period.
|
Hippocampal synaptic density and cumulative lifetime cannabis exposure.
Time Frame: Before and after the 4 week abstinence period.
|
To determine the relationship between hippocampal synaptic density (n=26+12 historical data) and indices of cannabis exposure such as cumulative lifetime cannabis exposure, as measured by self-report data.
|
Before and after the 4 week abstinence period.
|
Hippocampal SV2A synaptic density after 8 weeks
Time Frame: Approximately 8 CUD participants will be asked to return for a third [11C]APP311 (UCB-J) PET scan after an additional 4 weeks following their second scan. (8 weeks in total).
|
To explore whether hippocampal synaptic density and function continues to improve with 8 weeks of abstinence in a subset of CUD participants using [11C]APP311 (UCB-J).
|
Approximately 8 CUD participants will be asked to return for a third [11C]APP311 (UCB-J) PET scan after an additional 4 weeks following their second scan. (8 weeks in total).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Deepak C D'Souza, Yale University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2022
Primary Completion (Estimated)
May 1, 2027
Study Completion (Estimated)
May 1, 2032
Study Registration Dates
First Submitted
July 14, 2022
First Submitted That Met QC Criteria
July 20, 2022
First Posted (Actual)
July 25, 2022
Study Record Updates
Last Update Posted (Actual)
February 29, 2024
Last Update Submitted That Met QC Criteria
February 28, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000032181
- 1R01DA054314-01 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on [11C]APP311
-
Yale UniversityNational Institute on Drug Abuse (NIDA)RecruitingHealthy | Cannabis Use Disorder | Schizophrenia and Other Psychotic DisordersUnited States
-
Yale UniversityNational Center for Complementary and Integrative Health (NCCIH)RecruitingBehavior, HealthUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...RecruitingHealthy | Bipolar Disorder | Major Depressive DisorderUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH); National Institutes of Health (NIH)RecruitingHealthy | HIV Dementia | HIV Associated Neurocognitive Disorder | HIV EncephalitisUnited States
-
UCB PharmaYale University; PRA Health SciencesCompleted
-
Columbia UniversityRecruitingNeurodegenerative Diseases | Amyotrophic Lateral Sclerosis | Alzheimer DiseaseUnited States
-
National Institute of Mental Health (NIMH)TerminatedDementiaUnited States
-
Hoffmann-La RocheCompletedAlzheimer's Disease, Healthy VolunteerUnited States
-
Wendell Yap, MDUniversity of Kansas Medical CenterNo longer availableProstate CancerUnited States
-
Columbia UniversityCompleted